alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### Foreign-Trade Zones Board

          - [Order No. 1661]

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, the Board adopted the alternative site framework (ASF) in December 2008 (74 FR 1170, 01/12/09; correction 74 FR 3987, 01/22/09) as an option for the establishment or reorganization of general-purpose zones;

Whereas, the City and County of Butte-Silver Bow, Montana, grantee of Foreign-Trade Zone 274, submitted an application to the Board (FTZ Docket 33-2009, filed 8/4/2009) for authority to reorganize under the ASF with a service area of Butte-Silver Bow County, Montana, within and adjacent to the Butte-Silver Bow Customs and Border Protection port of entry, and FTZ 274's existing Site 1 would be categorized as a magnet site;

                    Whereas, notice inviting public comment was given in the                     **Federal Register**                     (74 FR 40566-40567, 8/12/09) and the application has been processed pursuant to the FTZ Act and the Board's regulations; and,                

Whereas, the Board adopts the findings and recommendation of the examiner's report, and finds that the requirements of the FTZ Act and Board's regulations are satisfied, and that the proposal is in the public interest;

Now, therefore, the Board hereby orders:

The application to reorganize FTZ 274 under the alternative site framework is approved, subject to the FTZ Act and the Board's regulations, including Section 400.28, and to the Board's standard 2,000-acre activation limit for the overall general-purpose zone project.

Signed at Washington, DC, this February 5, 2010.

Ronald K. Lorentzen,

Deputy Assistant Secretary for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2010-4054 Filed 2-25-10; 8:45 am]

BILLING CODE P
<PAGE>   1
                                   EXHIBIT 5.1

                          OPINION OF COOLEY GODWARD LLP

October 1, 1999

Vixel Corporation
11911 Northcreek Parkway South
Bothell, Washington  98011

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection
with the filing by Vixel Corporation (the "Company") of a Registration Statement
on Form S-8 (the "Registration Statement") with the Securities and Exchange
Commission covering the offering of up to 10,313,653 shares of the Company's
Common Stock, $0.001 par value (the "Shares"), pursuant to its 1995 Stock Option
Plan, 1999 Equity Incentive Plan and 1999 Employee Stock Purchase Plan (the
"Plans").

In connection with this opinion, we have examined the Registration Statement and
related Prospectus, your Restated Certificate of Incorporation, as amended, and
Bylaws, and such other documents, records, certificates, memoranda and other
instruments as we deem necessary as a basis for this opinion. We have assumed
the genuineness and authenticity of all documents submitted to us as originals,
the conformity to originals of all documents submitted to us as copies thereof,
and the due execution and delivery of all documents where due execution and
delivery are a prerequisite to the effectiveness thereof.

On the basis of the foregoing, and in reliance thereon, we are of the opinion
that the Shares, when sold and issued in accordance with the Plans, the
Registration Statement and related Prospectuses, will be validly issued, fully
paid, and non-assessable (except as to shares issued pursuant to certain
deferred payment arrangements, which will be fully paid and non-assessable when
such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration
Statement.

Very truly yours,

Cooley Godward LLP

/s/ Gregory B. Abbott

Gregory B. Abbott
§ 520.2075 Robenacoxib. ( a ) *Specifications.* Each tablet contains 10, 20, or 40 milligrams (mg) robenacoxib for use in dogs, or 6 mg robenacoxib for use in cats.
( b ) *Sponsors.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer 0.91 mg/lb (2 mg/kg) orally, once daily, for a maximum of 3 days.
( ii ) *Indications for use.* For the control of postoperative pain and inflammation associated with soft tissue surgery in dogs weighing at least 5.5 lb (2.5 kg) and at least 4 months of age for a maximum of 3 days.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cats* — ( i ) *Amount.* Administer 0.45 mg/lb (1 mg/kg) orally, once daily, for a maximum of 3 days.
( ii ) *Indications for use.* For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats weighing at least 5.5 lb (2.5 kg) and at least 4 months of age for a maximum of 3 days.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[76 FR 18648, Apr. 5, 2011, as amended at 79 FR 10964, Feb. 27, 2014; 81 FR 59133, Aug. 29, 2016]
1... See TEX. R. APP. P. 47.4.

 

2... The trial court and the district clerk’s office have advised this court that

they do not have any record that relator has filed a pending motion to compel.

Because relator’s motion has never been received by the trial court, Respondent

has not been provided an opportunity to rule upon the motion. Presentment of

the motion to the trial court is a prerequisite to mandamus relief. See O’Connor

v. First Court of Appeals, 837 S.W.2d 94, 97 (Tex. 1992).

COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 2-08-491-CV

IN RE DANIEL HARMON RELATOR

------------

ORIGINAL PROCEEDING

------------

MEMORANDUM OPINION1

------------

The court has considered relator’s petition for writ of mandamus and is

of the opinion that relief should be denied. Accordingly, relator’s petition for 2

writ of mandamus is denied.

Relator shall pay all costs of this original proceeding, for which let

execution issue.

PER CURIAM
2

PANEL: MCCOY and LIVINGSTON, JJ. 

DELIVERED: January 20, 2009
#### § 710.6 Notification of registrant; cosmetic product establishment registration number.

The Commissioner of Food and Drugs will provide the registrant with a validated copy of Form FD-2511 as evidence of registration. This validated copy will be sent only to the location shown for the registering establishment. A permanent registration number will be assigned to each cosmetic product establishment registered in accordance with the regulations in this part.
§ 582.5925 Valine. ( a ) *Product.* Valine (L- and DL-forms).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL  INFORMATION EXTACTED FROM THE GULFWEST
OIL COMPANY'S  QUARTELY REPORT FILED ON FORM 10-Q FOR THE QUARTE ENDED SEPTEMBER
30,  1998 AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
<CIK>                         0000813779
<NAME>                        0
<MULTIPLIER>                  1
<CURRENCY>                    0

<S>                            <C>
<PERIOD-TYPE>                  9-MOS
<FISCAL-YEAR-END>              DEC-31-1997
<PERIOD-START>                 JUL-01-1998
<PERIOD-END>                   SEP-30-1998
<EXCHANGE-RATE>                1
<CASH>                         0
<SECURITIES>                   0
<RECEIVABLES>                  751,227
<ALLOWANCES>                   0
<INVENTORY>                    0
<CURRENT-ASSETS>               902,608
<PP&E>                         23,958,890
<DEPRECIATION>                 3,673,603
<TOTAL-ASSETS>                 21,387,895
<CURRENT-LIABILITIES>          14,104,468
<BONDS>                        0
<PREFERRED-MANDATORY>          0
<PREFERRED>                    92
<COMMON>                       2,963
<OTHER-SE>                     1,606,935
<TOTAL-LIABILITY-AND-EQUITY>   21,387,895
<SALES>                        439,614
<TOTAL-REVENUES>               628,192
<CGS>                          0
<TOTAL-COSTS>                  1,129,512
<OTHER-EXPENSES>               0
<LOSS-PROVISION>               0
<INTEREST-EXPENSE>             (389,448)
<INCOME-PRETAX>                (890,768)
<INCOME-TAX>                   0
<INCOME-CONTINUING>            (890,768)
<DISCONTINUED>                 0
<EXTRAORDINARY>                0
<CHANGES>                      0
<NET-INCOME>                   (890,768)
<EPS-BASIC>                  (.32)
<EPS-DILUTED>                  (.32)


</TABLE>
§ 607.25 Information required for establishment registration and blood product listing. ( a ) The Blood Establishment Registration and Product Listing system requires furnishing or confirming registration information required by the Federal Food, Drug, and Cosmetic Act. This information includes the name and street address of the establishment, including post office code; a registration number if previously assigned by FDA and a Unique Facility Identifier in accordance with the system specified under section 510 of the Federal Food, Drug, and Cosmetic Act; all trade names used by the establishment; the kind of ownership or operation (that is, individually owned partnership, or corporation); and the name of the owner or operator of such establishment. The term “name of the owner or operator” must include, in the case of a partnership, the name of each partner and, in the case of a corporation, the name and title of each corporate officer and director and the name of the State of incorporation. The information required must be given separately for each establishment, as defined in § 607.3(c).
( b ) The following information must also be provided: ( 1 ) A list of blood products by established name as defined in section 502(e) of the Federal Food, Drug, and Cosmetic Act and by proprietary name, if any, which are being manufactured for commercial distribution at the identified establishment and which have not been included in any list previously submitted to FDA through the Blood Establishment Registration and Product Listing system or any future superseding electronic system.
( 2 ) For each blood product so listed that is subject to section 351 of the Public Health Service Act, the license number of the manufacturer issued by the Center for Biologics Evaluation and Research, Food and Drug Administration.
( 3 ) For each blood product listed, the registration number if previously assigned by FDA and the Unique Facility Identifier of the parent establishment. An establishment not owned, operated, or controlled by another firm or establishment is its own parent establishment.
[81 FR 60222, Aug. 31, 2016]
**IN THE SUPREME COURT OF THE STATE OF MONTANA**

RIVERSIDE MOBILE HOME & RV PARK, LLC,

Plaintiff/Appellee,

- vs DONALD BULLOCK and CYTHNIA BULLOCK, Defendants/Appellants.

_________________________________

______ ) ) ) ) ) ) ) ) ) ) ) Case No. DA 23 - 0494 **ORDER OF DISMISSAL WITH PREJUDICE**  Pursuant to the Parties’ Stipulation for Dismissal with Prejudice, and good cause appearing; IT IS HEREBY ORDERED that this matter is dismissed with prejudice, with each of the parties to bear its own costs and attorney’s fees.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

November 17 2023

11/17/2023 Case Number: DA 23-0494
Regulatory Evaluation

Complete when issuing a supplemental NPRM, revision, or supersedure.

 No Change from existing AD action

Docket No. FAA-2006-24785 Directorate Identifier: 2006-NE-20-AD

If you make changes to the values in the table below, you must ensure the totals update 

accordingly. If they do not, click (or Tab) into and then out of the changed cell.

Estimated Costs:

Action

(e.g., Inspection, 

replacement)

Costs per Product (e.g., aircraft, engine, 

propeller, appliance)

Work-hours

(include 

access, testing, 

and close-up)

Labor 

cost 

(@$85/h

our)

Parts Cost Total Costs 

(labor + 

parts)

Number of 

U.S. 

Registered

Products

Total Cost 

for U.S. Fleet

Replace crankshaft 0.0 $ 0.00 $16,000 $16,000.00 3,774 $60,384,000.

00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

$ 0.00 $ 0.00 $ 0.00

The known number of products in compliance:

Total Costs of compliance for U.S. fleet: $60,384,000

Costs covered under warranty (if known) $

Special considerations for Economic Analysis (Use this field to explain anything in the Estimated Costs 

table that was assumed or might not be obvious. This field can also be used to explain warranty costs): Same as 

original AD
Executive Order 12866:

Could the AD be considered a “significant regulatory action”?

YES* NO 

*Explanation: Original AD was not "significant".

DOT Regulatory Policies and Procedures:

Is the AD significant? 

YES* NO 

*Explanation: Original AD was not "significant".

Regulatory Flexibility Act:

Will the AD have a significant economic impact on a substantial number of small entities? Explain

for either a Yes or No answer.

YES NO 

Explanation: Original AD was not "significant".

Intrastate Aviation in Alaska:

This AD could affect intrastate aviation in Alaska. Is it appropriate to include specific requirements 

for aircraft operated in Alaska where aviation might be the only mode of transportation?

YES* NO 

*Explanation: This AD will be complyed with at engine overhaul or when other required 

maintenance is performed and therefore will not impact normal operations.
§ 582.6099 Tartaric acid. ( a ) *Product.* Tartaric acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
#### § 558.78 Bacitracin zinc.

(a) *Specifications.* Type A medicated articles containing bacitracin zinc equivalent to 10, 25, 40, or 50 grams per pound bacitracin.

(b) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.70 of this chapter.

(d) *Conditions of use.*

(1) It is used as follows:

| Bacitracin zinc in grams per ton | Combinations in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (i) 4 to 50 | | Chickens: for increased rate of weight gain and improved feed efficiency | Growing chickens | 054771 |
| (ii) 4 to 50 | | Turkeys and pheasants: for increased rate of weight gain and improved feed efficiency | Growing turkeys and pheasants | 054771 |
| (iii) 5 to 20 | | Quail; for increased rate of weight gain and improved feed efficiency | Growing quail; feed as the Type C feed to starting quail through 5 weeks of age | 054771 |
| (iv) 10 to 25 | | Laying chickens; improved feed efficiency and increased egg production | | 054771 |
| (v) 10 to 50 | | Swine; increased rate of weight gain and improved feed efficiency | Growing and finishing swine | 054771 |
| (vi) 20 | | Growing-finishing swine; increased rate of weight gain | In Type C feed | 054771 |
| (vii) 20 to 40 | | Growing-finishing swine; improved feed efficiency | ......do | 054771 |

(2) It is used in feed for growing cattle at 35 to 70 milligrams per head per day as follows:

(i) To aid in stimulating growth and improving feed efficiency.

(ii) For increased rate of weight gain and improved feed efficiency; see sponsor 054771.

(3) Bacitracin zinc may also be used in combination with:

(i) Amprolium and ethopabate as in § 558.58.

(ii) Clopidol as in § 558.175.

(iii) Decoquinate as in § 558.195.

(iv) Lasalocid as in § 558.311.

(v) Monensin as in § 558.355.

(vi) Naracin as in § 558.363.

(vii) Nicarbazin as in § 558.366.

(viii) Robenidine as in § 558.515.

(ix) Salinomycin as in § 558.550.

[41 FR 10994, Mar. 15, 1976]

###### Editorial Note

#### Editorial Note:

For Federal Register citations affecting § 558.78, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at *www.govinfo.gov.*
§ 520.2158 Streptomycin. ( a ) *Specifications.* Each milliliter of solution contains 250 milligrams (25 percent) streptomycin sulfate.
( b ) *Sponsor.* See No. 016592 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.610 of this chapter.
( d ) *Conditions of use.* Use in drinking water as follows: ( 1 ) *Calves* — ( i ) *Amount.* 10 to 15 milligrams per pound (mg/pound) of body weight (1.0 to 1.5 grams per gallon) for up to 5 days.
( ii ) *Indications for use.* For the treatment of bacterial enteritis caused by *Escherichia coli* and *Salmonella* spp. susceptible to streptomycin.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Swine* — ( i ) *Amount.* 10 to 15 mg/pound of body weight (1.0 to 1.5 grams per gallon) for up to 4 days.
( ii ) *Indications for use.* For the treatment of bacterial enteritis caused by *Escherichia coli* and *Salmonella* spp. susceptible to streptomycin.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 3 ) *Chickens* — ( i ) *Amount.* 10 to 15 mg/pound of body weight (0.6 to 0.9 grams per gallon) for up to 5 days.
( ii ) *Indications for use.* For the treatment of nonspecific infectious enteritis caused by organisms susceptible to streptomycin.
( iii ) *Limitations.* Withdraw 4 days before slaughter. Do not administer to chickens producing eggs for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37327, Aug. 18, 1992, as amended at 58 FR 47211, Sept. 8, 1993; 63 FR 51821, Sept. 29, 1998. Redesignated and amended at 79 FR 28828, May 20, 2014; 79 FR 74020, Dec. 15, 2014; 80 FR 18776, Apr. 8, 2015; 80 FR 61296, Oct. 13, 2015]
The Department of the Interior Mission

As the Nation's principal conservation agency, the Department of the Interior has responsibility 

for most of our nationally owned public lands and natural resources. This includes fostering 

sound use of our land and water resources; protecting our fish, wildlife, and biological diversity; 

preserving the environmental and cultural values of our national parks and historical places; 

and providing for the enjoyment of life through outdoor recreation. The Department assesses 

our energy and mineral resources and works to ensure that their development is in the best 

interests of all our people by encouraging stewardship and citizen participation in their care. 

The Department also has a major responsibility for American Indian reservation communities 

and for people who live in island territories under U.S. administration. 

The Minerals Management Service Mission 

As a bureau of the Department of the Interior, the Minerals Management Service's (MMS) 

primary responsibilities are to manage the mineral resources located on the Nation's Outer 

Continental Shelf (OCS), collect revenue from the Federal OCS and onshore Federal and Indian 

lands, and distribute those revenues. 

Moreover, in working to meet its responsibilities, the Offshore Minerals Management Program 

administers the OCS competitive leasing program and oversees the safe and environmentally 

sound exploration and production of our Nation's offshore natural gas, oil and other mineral 

resources. The MMS Minerals Revenue Management meets its responsibilities by ensuring the 

efficient, timely and accurate collection and disbursement of revenue from mineral leasing and 

production due to Indian tribes and allottees, States and the U.S. Treasury. 

The MMS strives to fulfill its responsibilities through the general guiding principles of: (1) being 

responsive to the public's concerns and interests by maintaining a dialogue with all potentially 

affected parties and (2) carrying out its programs with an emphasis on working to enhance the 

quality of life for all Americans by lending MMS assistance and expertise to economic 

development and environmental protection.
#### § 1316.05 Entry.

An inspection shall be carried out by an inspector. Any such inspector, upon (a) stating his purpose and (b) presenting to the owner, operator or agent in charge of the premises to be inspected (1) appropriate credentials, and (2) written notice of his inspection authority under § 1316.06 of this chapter, and (c) receiving informed consent under § 1316.08 or through the use of administrative warrant issued under §§ 1316.09-1316.13, shall have the right to enter such premises and conduct inspections at reasonable times and in a reasonable manner.

[36 FR 7820, Apr. 24, 1971, as amended at 36 FR 13387, July 21, 1971. Redesignated at 38 FR 26609, Sept. 24, 1973; 62 FR 13970, Mar. 24, 1997]
Office for Domestic Preparedness 

U.S. Department of Homeland Security 

Washington, DC 20531

ODP Information Bulletin 

No. 191 September 20, 2005 

TO All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 All State Homeland Security Directors 

FROM: Matt A. Mayer 

Acting Executive Director 

SUBJECT: Metropolitan Medical Response System (MMRS) Resources 

The MMRS program enables jurisdictions to achieve an enhanced local capability to respond to 

mass casualty events during the first hours of a response until significant external assistance can 

arrive. MMRS jurisdictions are prepared to respond to a range of mass casualty incidents—from 

weapons of mass destruction, epidemic outbreaks, natural disasters, and large-scale hazardous 

materials events. In FY 2005, the MMRS program addressed eight Capability Focus Areas 

including pharmaceutical cache management and the operational viability of mass care shelters 

and medical treatment facilities. 

Grantees are encouraged to use capabilities built through the MMRS program to support ongoing 

Hurricane Katrina recovery efforts, as appropriate, including: establishing reception centers, 

which consolidate monitoring, triage, decontamination, and registration of affected persons; 

ensuring that alternate medical treatment facilities have immediately available electric power, 

water and sewer, environmental controls, and other necessary infrastructure support; and 

strengthening medical surge capabilities by procuring additional medical supplies and 

pharmaceuticals. A list of eligible MMRS equipment, including medical supplies and 

pharmaceuticals, is available on the FY 2005 Authorized Equipment List, posted on the 

Responder Knowledge Base at www.rkb.mipt.org. 

These activities should be coordinated with other sources of Federal funding for relevant 

emergency medical and public health functions through the State Senior Advisory Committees. 

Additional questions may be directed to your Preparedness Officer or the Centralized Scheduling 

and Information Desk at askcsid@dhs.gov, 1-800-368-6498.